When to Order Imaging for Transgender Breast Cancer Screening: ACR Appropriateness Decoded
When to Order Imaging for Transgender Breast Cancer Screening: ACR Appropriateness Decoded
You’re evaluating a 42-year-old transfeminine patient for routine health maintenance. She has been on gender-affirming hormone therapy for seven years and has no personal or strong family history of breast cancer. She asks if she needs a mammogram. The guidelines for cisgender patients are clear, but applying them in the context of gender-affirming care requires specific knowledge. Choosing the right screening modality—or deciding if screening is indicated at all—is critical for providing equitable and evidence-based care. Here is how the American College of Radiology (ACR) Appropriateness Criteria guide imaging decisions for transgender breast cancer screening.
What Does ACR Transgender Breast Cancer Screening Cover?
These ACR Appropriateness Criteria provide evidence-based recommendations for breast cancer screening in asymptomatic transgender individuals. The guidelines are stratified based on several key factors: gender identity (transfeminine or transmasculine), duration of hormone therapy, personal and family risk factors for breast cancer, and history of gender-affirming chest surgery (such as mastectomy or breast reduction).
This topic specifically addresses screening for individuals without signs or symptoms of breast cancer, such as a palpable lump, nipple discharge, or skin changes. The evaluation of a new breast problem is considered a diagnostic workup and falls under separate ACR guidelines. The criteria detailed here help clinicians determine the appropriate initial imaging study for routine screening in various transgender patient populations, from average-risk individuals to those with a high lifetime risk of breast cancer.
What Imaging Should I Order for Transgender Breast Cancer Screening? Recommendations by Clinical Scenario
The appropriate imaging for transgender breast cancer screening depends heavily on the patient’s specific clinical context, including hormone use, surgical history, and underlying cancer risk. The ACR provides tailored recommendations for these distinct scenarios.
For a transfeminine (male-to-female) patient, age 40 or older, at average risk with 5 or more years of hormone use, both Digital Breast Tomosynthesis (DBT) and standard Mammography are rated as May be appropriate. The prolonged estrogen exposure increases breast cancer risk, justifying screening. In contrast, for an average-risk transfeminine patient with less than 5 years of hormone use (or no hormone use), screening with mammography, DBT, ultrasound, or MRI is Usually not appropriate, as their risk profile is considered similar to that of a cisgender male.
Risk stratification is key. For a higher-than-average risk transfeminine patient (e.g., with a genetic predisposition) who has used hormones for 5 or more years, screening with DBT or Mammography starting at age 25 to 30 is Usually appropriate. If the same high-risk patient has less than 5 years of hormone use, these modalities are downgraded to May be appropriate, reflecting a lower but still elevated risk.
For transmasculine (female-to-male) patients who have undergone bilateral mastectomies (“top surgery”), routine imaging screening of any kind is considered Usually not appropriate. While a small amount of breast tissue may remain, the risk of breast cancer is substantially reduced, and screening is not recommended.
However, for a transmasculine patient with remaining breast tissue (no chest surgery or only reduction mammoplasty), screening guidelines are similar to those for cisgender women. For an average-risk individual age 40 or older, DBT and Mammography are Usually appropriate. For an intermediate-risk patient (e.g., personal history of breast cancer) age 30 or older, DBT and Mammography remain Usually appropriate, while MRI and ultrasound May be appropriate as supplemental screening tools. For a high-risk transmasculine patient (e.g., genetic predisposition) age 25 to 30 or older, annual screening with DBT or Mammography is Usually appropriate, and annual screening with contrast-enhanced MRI is also Usually appropriate, mirroring high-risk cisgender screening protocols.
ACR Imaging Recommendations Table
| Clinical Scenario | Top Procedure | ACR Rating | Adult RRL | Pediatric RRL |
|---|---|---|---|---|
| Transfeminine, ≥40 yrs, ≥5 yrs hormones, average risk | Digital breast tomosynthesis screening | May be appropriate | ☢ ☢ 0.1-1mSv | |
| Transfeminine, ≥25-30 yrs, ≥5 yrs hormones, higher risk | Digital breast tomosynthesis screening | Usually appropriate | ☢ ☢ 0.1-1mSv | |
| Transfeminine, any age, <5 yrs hormones, average risk | US breast | Usually not appropriate | O 0 mSv | O 0 mSv [ped] |
| Transfeminine, ≥25-30 yrs, <5 yrs hormones, higher risk | Digital breast tomosynthesis screening | May be appropriate | ☢ ☢ 0.1-1mSv | |
| Transmasculine, bilateral mastectomies, any age/risk | US breast | Usually not appropriate | O 0 mSv | O 0 mSv [ped] |
| Transmasculine, no/reduced surgery, ≥40 yrs, average risk | Digital breast tomosynthesis screening | Usually appropriate | ☢ ☢ 0.1-1mSv | |
| Transmasculine, no/reduced surgery, ≥30 yrs, intermediate risk | Digital breast tomosynthesis screening | Usually appropriate | ☢ ☢ 0.1-1mSv | |
| Transmasculine, no/reduced surgery, ≥25-30 yrs, high risk | Digital breast tomosynthesis screening | Usually appropriate | ☢ ☢ 0.1-1mSv |
Adult vs. Pediatric Transgender Breast Cancer Screening Imaging: Radiation Dose Tradeoffs
The clinical scenarios for transgender breast cancer screening primarily focus on adults, with recommendations often beginning between ages 25 and 40. However, the principles of radiation safety, particularly As Low As Reasonably Achievable (ALARA), are crucial when considering imaging for any patient, especially younger individuals who may require screening over many decades. Cumulative radiation exposure is a significant concern in high-risk patients who begin screening at a young age.
The ACR Appropriateness Criteria include relative radiation level (RRL) indicators for this reason. Modalities like mammography and digital breast tomosynthesis (DBT) involve low-dose ionizing radiation (rated ☢ ☢, 0.1-1 mSv). In contrast, breast ultrasound and MRI involve no ionizing radiation (rated O, 0 mSv), making them safer from a radiation standpoint. The explicit notation of a zero-mSv dose for pediatric patients for US and MRI underscores their safety in younger populations. While these non-radiation modalities are not the primary screening tools for most scenarios, their lack of radiation is an important factor when they are considered for supplemental screening in high-risk individuals.
Imaging Protocol Details for Transgender Breast Cancer Screening
Once you’ve decided on the right study based on the ACR criteria, ensuring it is performed and interpreted correctly is the next step. The specific imaging protocol—including patient positioning, views, and contrast administration for MRI—is critical for diagnostic accuracy. Our protocol guides cover the technical details for the key studies recommended in these guidelines.
Tools to Help You Order the Right Study
Navigating imaging guidelines can be complex. GigHz offers a suite of reference tools designed to help clinicians make evidence-based decisions quickly and confidently at the point of care.
For clinical questions beyond transgender breast cancer screening, the ACR Appropriateness Criteria Lookup provides access to the full library of ACR guidelines, covering thousands of clinical variants across all specialties. It helps you find the right study for your patient’s specific presentation.
To ensure the selected study is performed to the highest standard, the Imaging Protocol Library offers detailed, step-by-step protocols for hundreds of imaging procedures. These guides are essential for standardizing care and optimizing image quality.
When discussing the risks and benefits of imaging with patients, especially concerning radiation, the Radiation Dose Calculator is an invaluable resource. It helps estimate cumulative radiation exposure from various imaging studies, facilitating informed patient conversations and adherence to ALARA principles.
Why is the 5-year hormone use threshold important for screening transfeminine individuals?
The 5-year threshold is based on evidence that prolonged exposure to exogenous estrogen, used in gender-affirming hormone therapy, is required to stimulate sufficient breast parenchymal development to increase breast cancer risk. Less than five years of use is generally not considered to elevate risk significantly above that of a cisgender male, making screening unnecessary for average-risk individuals.
Does a transmasculine patient post-mastectomy have zero risk of breast cancer?
No, the risk is not zero, but it is substantially reduced. During a mastectomy (“top surgery”), it is nearly impossible to remove 100% of the breast tissue. A small amount of residual tissue remains, particularly near the chest wall, axilla, and incision lines. While the ACR deems routine screening Usually not appropriate due to the low incidence, both patients and clinicians should remain vigilant for any new lumps or symptoms, which would warrant a diagnostic workup.
How do these screening guidelines for high-risk transgender individuals compare to those for high-risk cisgender women?
The guidelines are closely aligned. For high-risk individuals (e.g., BRCA gene mutation carriers, history of chest radiation), both high-risk transmasculine patients (with breast tissue) and high-risk cisgender women are recommended to begin annual mammography and annual contrast-enhanced breast MRI at a young age (typically 25-30). The principles of earlier and more intensive surveillance for high-risk groups are applied consistently.
Why isn’t breast ultrasound recommended as a primary screening tool?
While breast ultrasound is a valuable diagnostic tool for evaluating specific problems (like a palpable lump) and can be used for supplemental screening in dense breasts, it is not recommended as a primary, standalone screening modality. It has a higher rate of false positives compared to mammography and has not been shown in large trials to reduce mortality as a primary screening tool. Its role is typically adjunctive to mammography or MRI.
Is Digital Breast Tomosynthesis (DBT) better than standard 2D mammography for transgender patients?
The ACR rates both DBT and standard mammography similarly for most scenarios. However, DBT (or “3D mammography”) can be particularly beneficial as it reduces the effect of overlapping breast tissue, which can improve cancer detection rates and lower recall rates. This is especially relevant for transfeminine individuals on hormone therapy, which can increase breast density. When available, DBT is often preferred for screening.
Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 12, 2026
